Literature DB >> 8117905

Small-sample confidence sets for the MTD in a phase I clinical trial.

B E Storer1.   

Abstract

Properties of procedures for interval estimation of the maximum tolerable dose (MTD) in a Phase I clinical trial are examined, using a two-stage stochastic sampling scheme (Storer, 1989) as a paradigm for development. Although the likelihood function for the data arising from such a scheme is identical to one arising under a conditional binomial sampling assumption, intervals based on the exact distribution of the usual large-sample statistics under this assumption do not offer improvement over unadjusted intervals. However, consideration of the distribution of these statistics based on the true stochastic sampling scheme can lead to the construction of intervals with correct coverage probabilities that do not depend on the true values of the model parameters. Membership in the confidence set can be evaluated by Monte Carlo simulation at a restricted maximum likelihood estimate of the nuisance slope parameter, despite upward bias in its estimation from the up-and-down sampling scheme. The lack of information in the small-sample setting is reflected in a large proportion of confidence intervals that include infinite values for the MTD, especially when the dose-response curve is shallow. Intervals based on a likelihood ratio criterion perform best in this regard.

Mesh:

Substances:

Year:  1993        PMID: 8117905

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  3 in total

1.  Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.

Authors:  Raya Mawad; Ted A Gooley; Joseph G Rajendran; Darrell R Fisher; Ajay K Gopal; Andrew T Shields; Brenda M Sandmaier; Mohamed L Sorror; Hans Joachim Deeg; Rainer Storb; Damian J Green; David G Maloney; Frederick R Appelbaum; Oliver W Press; John M Pagel
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-20       Impact factor: 5.742

2.  Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.

Authors:  John M Pagel; Theodore A Gooley; Joseph Rajendran; Darrell R Fisher; Wendy A Wilson; Brenda M Sandmaier; Dana C Matthews; H Joachim Deeg; Ajay K Gopal; Paul J Martin; Rainer F Storb; Oliver W Press; Frederick R Appelbaum
Journal:  Blood       Date:  2009-09-28       Impact factor: 22.113

3.  Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia.

Authors:  Phuong Vo; Ted A Gooley; Joseph G Rajendran; Darrell R Fisher; Johnnie J Orozco; Damian J Green; Ajay K Gopal; Robyn Haaf; Margaret Nartea; Rainer Storb; Frederick R Appelbaum; Oliver W Press; John M Pagel; Brenda M Sandmaier
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.